---
created: 2025-04-13
updated: 2025-04-13T10:52
id: yzqWy9=#J{
specialty: immuno
specialty_id: 96
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::01-immunosuppressants
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::01-immunosuppressants::basiliximab
  - "source/ak-step1-v11:": 
  - theme/ome::07-immunology::16-immunosuppression
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::07-immunology::16-immunosuppression
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::01-immunology::04-basiliximab
  - "source/ak-step1-v11:": 
  - theme/pixorize::01-immunology::05-cytokines::03-il-2
  - "source/ak-step1-v11:": 
  - theme/pixorize::01-immunology::09-immunosuppressants::04-basiliximab
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::immunology-&-biochemistry-pharmacology::immuno-suppressives::transplant-rejection-prophylaxis
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield"
type: flashcard
---

# Question
Basiliximab is a monoclonal antibody that blocks the **IL-2** receptor

---

# Answer
Specifically the high affinity variant (CD25)